| Dr Ellery Reyes Ho, DPM | |
|
425 Huehl Rd, Unit #13, Northbrook, IL 60062-2319 | |
| (847) 504-5000 | |
| (847) 504-5015 |
| Full Name | Dr Ellery Reyes Ho |
|---|---|
| Gender | Male |
| Speciality | Podiatry |
| Experience | 22 Years |
| Location | 425 Huehl Rd, Northbrook, Illinois |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285668459 | NPI | - | NPPES |
| 200247020A | Medicaid | IN | |
| 0732240001 | Other | DMERC # WITH PPG |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 213E00000X | Podiatrist | 07000983A (Indiana) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Preferred Podiatry Group Pc | 3971412677 | 114 |
News Archive
Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.
Listening to a conversation in the context of a cocktail party presents a great challenge for the auditory system.
Patients with double hit lymphoma (DHL) who undergo autologous stem-cell transplantation (autoSCT) after achieving remission are not more likely to remain in remission or live longer than patients who do not undergo autoSCT, according to a new analysis from the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
Poorly controlled asthma more than doubles healthcare costs associated with the disease and threatens educational achievement through a dramatic increase in school absence, according to researchers at National Jewish Health.
› Verified 6 days ago
| Provider Name | Preferred Podiatry Group Pc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1720037138 PECOS PAC ID: 3971412677 Enrollment ID: O20040612000269 |
News Archive
Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.
Listening to a conversation in the context of a cocktail party presents a great challenge for the auditory system.
Patients with double hit lymphoma (DHL) who undergo autologous stem-cell transplantation (autoSCT) after achieving remission are not more likely to remain in remission or live longer than patients who do not undergo autoSCT, according to a new analysis from the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
Poorly controlled asthma more than doubles healthcare costs associated with the disease and threatens educational achievement through a dramatic increase in school absence, according to researchers at National Jewish Health.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Ellery Reyes Ho, DPM 425 Huehl Rd, Unit #13, Northbrook, IL 60062-2319 Ph: (847) 504-5000 | Dr Ellery Reyes Ho, DPM 425 Huehl Rd, Unit #13, Northbrook, IL 60062-2319 Ph: (847) 504-5000 |
News Archive
Despite the promising findings of the PROTECT Pilot study, the larger PROTECT trial found no difference with rolofylline versus placebo with respect of the primary and main secondary end-points of the study. Although more rolofylline patients than placebo patients experienced moderate or marked dyspnea improvement at 24 and 48 hours from randomization, this was counterbalanced by a lack of effect on persistent renal impairment. Lastly, the risk of important neurological events was increased in patients on rolofylline.
Listening to a conversation in the context of a cocktail party presents a great challenge for the auditory system.
Patients with double hit lymphoma (DHL) who undergo autologous stem-cell transplantation (autoSCT) after achieving remission are not more likely to remain in remission or live longer than patients who do not undergo autoSCT, according to a new analysis from the Perelman School of Medicine and the Abramson Cancer Center of the University of Pennsylvania.
Halozyme Therapeutics, Inc. today announced the initiation of two Phase 2 Ultrafast Insulin treatment studies that utilize its rHuPH20 hyaluronidase enzyme (PH20) in combination with the two leading commercially available mealtime analogs: insulin aspart, the active ingredient in NovoLog®, and insulin lispro, the active ingredient in Humalog®.
Poorly controlled asthma more than doubles healthcare costs associated with the disease and threatens educational achievement through a dramatic increase in school absence, according to researchers at National Jewish Health.
› Verified 6 days ago
Dr. Mollye Deborah Karp, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 425 Huehl Rd Unit 13, Northbrook, IL 60062 Phone: 847-504-5000 Fax: 847-504-5015 | |
Dr. Sanford Mason, DPM Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 425 Huehl Rd, #13, Northbrook, IL 60062 Phone: 847-504-5000 Fax: 847-504-5015 | |
Dr. Francine Christina Rhinehart, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 425 Huehl Rd # 13, Northbrook, IL 60062 Phone: 847-504-5000 Fax: 847-504-5015 | |
Affiliated Podiatrists Of Illinois Ltd. Podiatrist Medicare: Not Enrolled in Medicare Practice Location: 350 Oak Knoll Ter, Northbrook, IL 60062 Phone: 847-562-9864 Fax: 847-562-9865 | |
Dr. Richard Lane Kusunose, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 40 Skokie Blvd Ste 520, Northbrook, IL 60062 Phone: 847-504-5000 Fax: 847-504-5015 | |
Dr. Suzanne Roeckell Moreno, DPM Podiatrist Medicare: Accepting Medicare Assignments Practice Location: 40 Skokie Blvd Ste 520, Northbrook, IL 60062 Phone: 847-504-5000 Fax: 847-504-5015 | |
Absolute Foot And Ankle Clinic Ltd Podiatrist Medicare: Medicare Enrolled Practice Location: 3546 N Milwaukee Ave, Northbrook, IL 60062 Phone: 847-297-9660 Fax: 847-297-9665 |